Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Resectable Gastric and Gastroesophageal Junction Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 0 results

Not applicableUnknownNCT04269083
What this trial is testing

A Biomarker-driven Therapeutic Strategy for Esophageal Cancer Chemoradiotherapy in Patients With Resectable Adenocarcinoma of the ESophagus and Esophagogastric Junction

Who this might be right for
Esophageal Cancer
Azienda Ospedaliera Universitaria Integrata Verona 128
Large-scale testing (Phase 3)Study completedNCT00002883
What this trial is testing

Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus

Who this might be right for
Esophageal CancerGastric Cancer
UNICANCER 250
Testing effectiveness (Phase 2)Study completedNCT01077999
What this trial is testing

Chemoradiation and Panitumumab for Esophageal Cancer

Who this might be right for
Squamous Cell CarcinomaAdenocarcinomaEsophageal Cancer+1 more
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 78
Post-approval studies (Phase 4)Not Yet RecruitingNCT07161453
What this trial is testing

Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology

Who this might be right for
Gastric / Gastroesophageal Junction Adenocarcinoma
Liaoning Cancer Hospital & Institute 500
Large-scale testing (Phase 3)Looking for participantsNCT07643623
What this trial is testing

Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. 720
Testing effectiveness (Phase 2)Looking for participantsNCT07483567
What this trial is testing

IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
CLDN18.2 PositivePrimary Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd. 90
Testing effectiveness (Phase 2)Looking for participantsNCT07631000
What this trial is testing

Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric CancerGastroesophageal-junction Cancer
Memorial Sloan Kettering Cancer Center 37
Large-scale testing (Phase 3)UnknownNCT01523015
What this trial is testing

Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction

Who this might be right for
Adenocarcinoma of the Gastroesophageal Junction
Medical University of Lublin 100
Testing effectiveness (Phase 2)Looking for participantsNCT04908566
What this trial is testing

Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Locally Advanced Gastric Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital 124
Large-scale testing (Phase 3)Looking for participantsNCT04447352
What this trial is testing

HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Krankenhaus Nordwest 200
Testing effectiveness (Phase 2)WithdrawnNCT07283848
What this trial is testing

Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma

Who this might be right for
Adenocarcinoma StomachAdenocarcinoma Gastroesophageal Junction
Massachusetts General Hospital
Testing effectiveness (Phase 2)Temporarily pausedNCT06250036
What this trial is testing

Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

Who this might be right for
Locally Advanced Gastric AdenocarcinomaMSI-H/dMMR Gastric CancerMSI-H/dMMR Gastroesophageal-junction Cancer
Royal Marsden NHS Foundation Trust 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT05836584
What this trial is testing

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Who this might be right for
Clinical Stage I Gastric Cancer AJCC v8Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage II Gastric Cancer AJCC v8+7 more
National Cancer Institute (NCI) 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT03773367
What this trial is testing

Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.

Who this might be right for
Resectable Gastric and Gastroesophageal Junction Adenocarcinoma
Lund University Hospital 60